These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20490777)

  • 21. The molecular biology of cancer. Part 2--Why cancers can outsmart our immune systems!
    Cohen HV; Quek SY
    J N J Dent Assoc; 2011; 82(2):34-6. PubMed ID: 21877656
    [No Abstract]   [Full Text] [Related]  

  • 22. Cancer despite immunosurveillance: immunoselection and immunosubversion.
    Zitvogel L; Tesniere A; Kroemer G
    Nat Rev Immunol; 2006 Oct; 6(10):715-27. PubMed ID: 16977338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
    Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
    Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.
    Ramanathan S; Gagnon J; Ilangumaran S
    Arch Immunol Ther Exp (Warsz); 2008; 56(5):311-23. PubMed ID: 18836862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
    Ward PL; Koeppen HK; Hurteau T; Rowley DA; Schreiber H
    Cancer Res; 1990 Jul; 50(13):3851-8. PubMed ID: 2112981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoregulatory T cells in tumor immunity.
    Terabe M; Berzofsky JA
    Curr Opin Immunol; 2004 Apr; 16(2):157-62. PubMed ID: 15023407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The paradox of pro-inflammatory cytokines in cancer.
    Dinarello CA
    Cancer Metastasis Rev; 2006 Sep; 25(3):307-13. PubMed ID: 17029030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response.
    Eksioglu EA; Mahmood SS; Chang M; Reddy V
    Exp Hematol; 2007 Aug; 35(8):1163-71. PubMed ID: 17562355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory skin diseases, T cells, and immune surveillance.
    Robert C; Kupper TS
    N Engl J Med; 1999 Dec; 341(24):1817-28. PubMed ID: 10588968
    [No Abstract]   [Full Text] [Related]  

  • 35. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
    Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
    Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The two sides of HER2/neu: immune escape versus surveillance.
    Seliger B; Kiessling R
    Trends Mol Med; 2013 Nov; 19(11):677-84. PubMed ID: 24035606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticle-based immunotherapy for cancer.
    Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
    ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-23 promotes tumour incidence and growth.
    Langowski JL; Zhang X; Wu L; Mattson JD; Chen T; Smith K; Basham B; McClanahan T; Kastelein RA; Oft M
    Nature; 2006 Jul; 442(7101):461-5. PubMed ID: 16688182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities.
    Massa C; Seliger B
    J Immunol; 2013 Apr; 190(7):3328-37. PubMed ID: 23447683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.